Kymera Therapeutics (KYMR) PT Lowered to $119 at Morgan Stanley

April 30, 2026 12:01 PM

Morgan Stanley analyst Judah Frommer lowered the price target on Kymera Therapeutics (NASDAQ: KYMR) to $119.00 (from $123.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found